Therapeutic Advances in Hematology

Papers
(The H4-Index of Therapeutic Advances in Hematology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide28
Prognostic impact of IL7R mutations on acute myeloid leukemia27
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study27
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria27
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine24
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy24
Brain iron content and cognitive function in patients with β-thalassemia22
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors21
Treatment of multiple myeloma: What is the impact on T-cell function?20
Macrofocal multiple myeloma in the era of novel agents in China19
Role of abatacept in the prevention of graft-versus-host disease: current perspectives19
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia18
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes15
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma15
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China15
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente15
0.048909902572632